Abstract
B-cell clones can produce a monoclonal immunoglobulin, which may be responsible for visceral involvements. Kidney involvement is frequent, affecting 20 to 50% of patients with multiple myeloma. One mechanism underlying this involvement is a dysregulation of the complement alternative pathway, leading to C3 glomerulopathies. We report a patient who had a multiple myeloma, C3 glomerulopathy related to factor H autoantibody, and digital ischemia, who was treated successfully with eculizumab, an anti-complement therapy, without any relapse in 2 years of follow-up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH, on behalf of the International Kidney and Monoclonal Gammopathy Research Group (2015) Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87:698–711. https://doi.org/10.1038/ki.2014.408
Blanc C, Togarsimalemath SK, Chauvet S, le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA (2015) Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 194:5129–5138. https://doi.org/10.4049/jimmunol.1402770
Le Quintrec M, Lionet A, Kandel C et al (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65:484–489. https://doi.org/10.1053/j.ajkd.2014.09.025
Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F (2017) Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129:1437–1447. https://doi.org/10.1182/blood-2016-08-737163
Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C (2015) Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgAλ antibody. Am J Kidney Dis 66:331–336. https://doi.org/10.1053/j.ajkd.2015.03.039
Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331–e335. https://doi.org/10.1542/peds.2012-0903
Sathe KP, Ohri A, Mishra A, Ali U (2016) Digital gangrene in a child with atypical hemolytic uremic syndrome associated with anti-factor H antibodies. Indian J Nephrol 26:231–232. https://doi.org/10.4103/0971-4065.169557
Ferluga J, Kishore U, Sim RB (2014) A potential anti-coagulant role of complement factor H. Mol Immunol 59:188–193. https://doi.org/10.1016/j.molimm.2014.02.012
Turner N, Nolasco L, Nolasco J, Sartain S, Moake J (2014) Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 40:544–550. https://doi.org/10.1055/s-0034-1383547
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Deshayes, S., Martin Silva, N., Chatelet, V. et al. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Clin Rheumatol 37, 1119–1122 (2018). https://doi.org/10.1007/s10067-018-4058-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4058-6